Positron Emission Tomography Clinical Trials

21 recruitingLast updated: June 18, 2026

There are 21 actively recruiting positron emission tomography clinical trials across 8 countries. Studies span Not Applicable, Early Phase 1, Phase 3, Phase 2. Top locations include Tianjin, Tianjin Municipality, China, Exeter, Devon, United Kingdom, Hefei, Anhui, China. Updated daily from ClinicalTrials.gov.


Positron Emission Tomography Trials at a Glance

21 actively recruiting trials for positron emission tomography are listed on ClinicalTrialsFinder across 6 cities in 8 countries. The largest study group is Not Applicable with 6 trials, with the heaviest enrollment activity in Tianjin, Exeter, and Hefei. Lead sponsors running positron emission tomography studies include Tianjin Medical University, Huashan Hospital, and First Affiliated Hospital of Chongqing Medical University.

Browse positron emission tomography trials by phase

Treatments under study

About Positron Emission Tomography Clinical Trials

Looking for clinical trials for Positron Emission Tomography? There are currently 21 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Positron Emission Tomography trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Positron Emission Tomography clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 21 trials

Recruiting

Programmed Cell Death Ligand 1 PET/CT in Various PD-L1-Related Disease Patients

PD-L1 Gene MutationPositron Emission TomographyPD-L1 Gene Amplification+1 more
Tianjin Medical University500 enrolled2 locationsNCT07618936
Recruiting
Early Phase 1

iMagemHTT-009- FIH Evaluation of Novel Mutant Huntingtin PET Radioligand [11C]CHDI-00491009

Huntington’s DiseaseHuntington DiseasePositron Emission Tomography+6 more
CHDI Foundation, Inc.27 enrolled1 locationNCT06634628
Recruiting
Not Applicable

Metastasis Directed Stereotactic Body Radiotherapy for Oligo Metastatic Hormone Sensitive Prostate Cancer

Prostate Cancer MetastaticPositron Emission TomographyRadiation Therapy
Karin Soderkvist118 enrolled7 locationsNCT04983095
Recruiting

Serotonin Release in Premotor and Motor PD

Parkinson DiseasePositron Emission TomographyNeurodegenerative Diseases+3 more
University of Exeter42 enrolled1 locationNCT05516732
Recruiting

Longitudinal Investigation of I2BS in PD

Parkinson DiseasePositron Emission TomographyNeurodegenerative Diseases+3 more
University of Exeter44 enrolled1 locationNCT05516719
Recruiting
Phase 3

PSMA PET Combined With MRI for the Detection of PCa

Prostate CancerProstatic NeoplasmPCA+6 more
Telix Pharmaceuticals (Innovations) Pty Limited204 enrolled1 locationNCT07052214
Recruiting

Prostate Specific Membrane Antigen PET/CT Imaging in PSMA-Related Disease Patients

Prostate CancerMetastasisPositron Emission Tomography+2 more
Tianjin Medical University500 enrolled2 locationsNCT06690970
Recruiting
Not Applicable

68Ga-FAPI-LM3 PET/CT Imaging in Patients With FAP/SSTR2 Positive Disease and Compared With 18F-FDG

Positron Emission TomographyFAPSSTR2
The First Affiliated Hospital of Xiamen University30 enrolled1 locationNCT05873777
Recruiting
Phase 2Phase 3

Pancreatic Cancer Diagnosis With FAPI-PET Imaging

Pancreatic CancerFAPIPositron Emission Tomography+5 more
Turku University Hospital100 enrolled1 locationNCT07098598
Recruiting
Early Phase 1

NeuroFLiPP: Parametric PET of Neuroinflammation in Fatty Liver Disease

Positron Emission Tomography
University of California, Davis12 enrolled1 locationNCT06453915
Recruiting

Establishment of the Chinese Preclinical Alzheimer's Disease Study With Multiple Neuroimaging

Alzheimer DiseasePositron Emission Tomography
Huashan Hospital3,000 enrolled1 locationNCT06827678
Recruiting
Early Phase 1

[68Ga]Ga-Sa-DABI-4 PET Imaging of Stimulator of Interferon Gene Expression in Cancer Patients

CancerPositron Emission TomographyStimulator of Interferon Gene
First Affiliated Hospital of Chongqing Medical University30 enrolled1 locationNCT06419361
Recruiting
Early Phase 1

68Ga-PSFA PET Imaging in Patients With PSMA/FAP Positive Disease

Positron Emission TomographyFAPPSMA
First Affiliated Hospital of Chongqing Medical University30 enrolled1 locationNCT06387381
Recruiting
Not Applicable

Chemokine Receptor 4 PET/CT Imaging of CXCR4-Related Diseases

MetastasisTumorPositron Emission Tomography+1 more
Tianjin Medical University200 enrolled1 locationNCT06690736
Recruiting

Glucagon-like Peptide-1 Receptor PET/CT in GLP-1R Related Disease

TumorPositron Emission TomographyGLP1-R-related Disease+1 more
Tianjin Medical University500 enrolled1 locationNCT06725693
Recruiting

FAPI PET/CT in Various FAP-Related Disease Patients

MetastasisTumorPositron Emission Tomography+1 more
Tianjin Medical University500 enrolled1 locationNCT06688071
Recruiting

Somatostatin Receptor PET/CT in SSTR-Related Disease Patients

MetastasisTumorPositron Emission Tomography+1 more
Tianjin Medical University500 enrolled1 locationNCT06690957
Recruiting
Not Applicable

The Role of Imaging in the Diagnosis, Management and Prognosis of Possible Non-convulsive Status Epilepticus

Positron Emission TomographyStatus EpilepticusIctal-interictal Continuum+2 more
Universitaire Ziekenhuizen KU Leuven200 enrolled1 locationNCT06017973
Recruiting

Gene Expression Profiles in Spinal Tuberculosis.

Musculoskeletal DiseasesTuberculosisInfections+11 more
University of Cape Town100 enrolled1 locationNCT05610098
Recruiting
Not Applicable

Clinical Study of TROP-2 PET/CT for Noninvasive Diagnosis of Solid Tumors

NeoplasmsPositron Emission Tomography
Huashan Hospital60 enrolled1 locationNCT06203574